Latest CRISPR Therapeutics News & Updates

See the latest news and media coverage for CRISPR Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

CRISPR Therapeutics

Gene-editing therapeutics developer

crisprtx.com

Headquarters: Boston, United States
Founded year: 2013
Company type: Public company
Number of employees: 350–500

Last updated Today

Latest news about CRISPR Therapeutics

Company announcements

May 4 CRISPR Therapeutics

CRISPR Therapeutics reported Q1 2026 financial results and business update

Revenue included $43M from CASGEVY, cash increased to $2.44B, and development milestones advanced across pipeline.

March 10 CRISPR Therapeutics

CRISPR Therapeutics announces proposed $350M convertible senior notes offering

The notes due 2031 will be offered to qualified institutional buyers in a private offering.

February 12 CRISPR Therapeutics

CRISPR Therapeutics reports Q4 and full year 2025 financial results

CASGEVY generated $116M in 2025 revenue, with 64 patient infusions, and pipeline advances in autoimmune, oncology, and in vivo programs.

January 12 CRISPR Therapeutics

CRISPR Therapeutics highlights strategic priorities and 2026 milestones

CASGEVY revenue exceeded $100M in 2025; clinical data from CTX310, CTX611, and zugo-cel expected in 2026.

Media coverage

Yesterday Yahoo Finance

Eli Lilly Just Proved Gene Editing Could Be Pharma s Next Gold Rush -- but CRISPR Therapeutics Investors Should Watch Out

Eli Lilly's work in gene editing be it? Let's look at recent clinical trial results for one of Eli...

June 1 Yahoo Finance

CRISPR Therapeutics Conferences May Reframe Valuation Gap And Growth Outlook

CRISPR Therapeutics (NasdaqGM:CRSP) is set to participate in several major healthcare investor...

May 22 Insider Monkey

CRISPR Therapeutics AG (CRSP) Reports Q1 2026 Results

On May 4, CRISPR Therapeutics AG (NASDAQ:CRSP) reported its first quarter 2026 results and advanced its pipeline and commercial launch.

May 18 Yahoo Finance

CRISPR Therapeutics Enters Second Phase As CASGEVY Uptake And Data Build

CRISPR Therapeutics (NasdaqGM:CRSP) is entering a second phase of its business as the CASGEVY commercial rollout gains momentum. The company reports new patient initiations for...

Never miss news about CRISPR Therapeutics

Track CRISPR Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.